BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $3692.HK readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07879885-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:HS-20137 readout (P2) · Hansoh BioMedical R&D Company $3692.HK
DESCRIPTION:An Open-label Study of HS-20137 in Participants With Moderate-t
 o-Severe Plaque Psoriasis\n\nPrimary completion date: 2027-03-01 (estimate
 d)\nPhase 2 · Immuno · Moderate-to-severe Plaque Psoriasis\nEnrollment: 
 390 · Sites: 1\n\nPrimary completion = last participant's primary-endpoin
 t data collected\; topline results usually follow weeks to months later. S
 ponsor-reported\, often an estimate. Not investment advice.\n\nhttps://dat
 acutoff.com/radar.html?nct=NCT07879885\nhttps://clinicaltrials.gov/study/N
 CT07879885
URL:https://datacutoff.com/radar.html?nct=NCT07879885
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855069-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270307
DTEND;VALUE=DATE:20270308
SUMMARY:HS-20089 readout (P3) · Hansoh BioMedical R&D Company $3692.HK
DESCRIPTION:HS-20089 for Injection in Patients With Platinum-Resistant Recu
 rrent Epithelial Ovarian Cancer\n\nPrimary completion date: 2027-03-07 (es
 timated)\nPhase 3 · Oncology · Ovarian Cancer\nEnrollment: 468 · Sites:
  1\n\nPrimary completion = last participant's primary-endpoint data collec
 ted\; topline results usually follow weeks to months later. Sponsor-report
 ed\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/r
 adar.html?nct=NCT06855069\nhttps://clinicaltrials.gov/study/NCT06855069
URL:https://datacutoff.com/radar.html?nct=NCT06855069
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844799-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HS-20137 readout (P3) · Hansoh BioMedical R&D Company $3692.HK
DESCRIPTION:A Study of HS-20137 in Participants with Moderate-to-severe Pla
 que Psoriasis\n\nPrimary completion date: 2027-03-31 (estimated)\nPhase 3 
 · Immuno · Moderate-to-severe Plaque Psoriasis\nEnrollment: 720 · Sites
 : 0\n\nPrimary completion = last participant's primary-endpoint data colle
 cted\; topline results usually follow weeks to months later. Sponsor-repor
 ted\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/
 radar.html?nct=NCT06844799\nhttps://clinicaltrials.gov/study/NCT06844799
URL:https://datacutoff.com/radar.html?nct=NCT06844799
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
